Home › Anemia › Florida › Tampa
Anemia clinical trials in Tampa, FL
5 studies for Anemia are looking for participants at sites in and around Tampa (within about 30 miles). Open a study to see who can join and how to contact the study team.
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
Study of DISC-0974-201 in Participants With IBD and Anemia
RecruitingPhase 2
- Guardian Angel Research, Inc, Tampa
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RecruitingPhase 3
- Moffitt Cancer Center, Tampa
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
RecruitingPhase 3
- Moffit Cancer Center, Tampa
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RecruitingPhase 3
- Moffitt Cancer Center, Tampa
About Anemia
Anemia occurs when your blood doesn't carry enough oxygen to the rest of your body. Read about conditions that lead to it and treatments available.
More about Anemia on MedlinePlus
Anemia trials in other cities
- New York City, NY7 studies
- Atlanta, GA6 studies
- Miami, FL6 studies
- Philadelphia, PA6 studies
- Houston, TX5 studies
- Baldwin Park, CA4 studies
- St. Louis, MO4 studies
- Winston-Salem, NC4 studies
- Cleveland, OH4 studies
- Washington, DC3 studies
- Edison, NJ3 studies
- Portland, OR3 studies
Other studies in Tampa
- Non-Small Cell Lung Cancer51 studies
- Breast Cancer43 studies
- Cancer (all types)39 studies
- Colorectal Cancer33 studies
- Lung Cancer29 studies
- Metastatic Cancer29 studies
- Acute Myeloid Leukemia29 studies
- Pancreatic Cancer27 studies
- Ovarian Cancer20 studies
- Melanoma19 studies
- Myelodysplastic Syndromes19 studies
- Prostate Cancer19 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.